Loading stock data…
$1.40-0.04 (-2.60%)
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom.
OKYO Pharma Limited in the Healthcare sector is trading at $1.40 with a market capitalization of $75M. Wall Street consensus targets $8.33 (3 analysts), implying a +495.2% move over the next 12 months. The stock is currently near its 52-week low of $1.26, remaining 16.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q3 2025 | Q1 2025 | Q3 2024 | Q1 2024 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry ey...